The AstraZeneca share price has smashed the FTSE 100 in 2018. I say it could do so again in 2019

Rupert Hargreaves explains why he thinks AstraZeneca plc (LON:AZN) will continue to outperform the FTSE 100 (INDEXFTSE: UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are only a few stocks in the FTSE 100 that have outperformed the blue-chip index this year. AstraZeneca (LSE: AZN) is one of these. Year-to-date, the stock is up 21.3%, excluding dividends, compared to a loss of 6.4% for the FTSE 100. 

Including dividends, Astra’s performance is even more impressive. The stock is up 23.4% in 2018, compared to a loss of 5.4% for the UK’s leading blue-chip index, a total outperformance of 28.8%. 

You might think that after this market-beating performance in 2018, shares in Astra are set to lag the FTSE 100 in 2019. However, reckon the firm will continue to lead the index higher next year. Here’s why. 

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Pushing ahead

Astra has come a long way since 2014 when US drugs giant Pfizer tried to acquire the business for £69.4bn. When management rejected the £55-a-share deal, a 45% premium over the share price at the time, investors analysts were sceptical that it was making the right decision. 

Four years on, and it looks as if management did chose the right path. While the buyout might have delivered a quick return for investors, if you’d invested £10,000 in Astra back in 2014, today it would be worth over £20,000, including reinvested dividends. In other words, shareholders have benefited significantly from the deal not going ahead. 

But what does the future hold for the company? Well, 2018 has been somewhat of an inflection year for the firm. After a wave of new treatment launches, for the first time in four years, the group’s sales increased by 9% in the third quarter. On a statutory basis, total revenue for the nine months fell 6% to $15.7bn. 

I think this is a sign of things to come. Third quarter sales momentum is set to continue “into the fourth quarter and beyond,” according to Mark Mallon, Astra’s executive vice-president of global product. New medicines and growth in emerging markets have helped offset sales declines in the group’s legacy product portfolio, which includes the former blockbuster blood pressure drug Crestor. Sales of Crestor continue to decline as the product suffers from growing generic competition. 

City analysts expect this top-line growth to start benefitting Astra’s bottom line this year. The City has pencilled in earnings per share (EPS) of $3.41 for 2018, up 55.7% year-on-year. EPS are expected to expand further in 2019, growing just under 13% to $3.83. 

Investors returning 

In my opinion, this earnings growth should convince more investors to return, as the company proves that its recovery is well and truly underway. 

What’s more, as earnings expand, Astra’s dividend cover is set to rise to 1.4 times next year. For four of the past five years, the dividend hasn’t been wholly covered by EPS.

With Astra’s income credentials improving, and earnings expanding again, I think it’s highly likely that the stock will continue to outperform the market in 2019. And if it doesn’t, investors are still set to receive a dividend yield of 3.6%, significantly above the interest rate on offer from most savings accounts today.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

2 beaten-down shares to consider buying for a stock market recovery

The stock market is rebounding from a violent sell-off triggered by the 'Liberation Day' tariff chaos. This pair of shares…

Read more »

Man riding the bus alone
Investing Articles

Is the GSK share price finally getting its act together?

The GSK share price has had a horrible millennium. Harvey Jones can't believe how bad it's been. But are we…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

The BT share price jumps again… have investors missed their chance?

The BT share price has surged since Dr James Fox added it to his watchlist. He explores whether there’s still…

Read more »

piggy bank, searching with binoculars
Investing Articles

Up 27% in May! I’m betting International Consolidated Airlines (IAG) shares will smash the FTSE 100 again

Harvey Jones feared he'd missed his chance to buy International Consolidated Airlines (LSE:IAG) shares last year. He got a second…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

These 3 UK stocks are set for promotion to the FTSE 250. Should I buy any of them?

Of the trio of UK stocks soon set to join the FTSE 250 (INDEXFTSE:MCX) index, only one of them has…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

The Jet2 share price has surged 63% since April…

Dr James Fox said the Jet2 share price would surged in 2025, and it has. After US trade policy pushed…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Can Lloyds’ share price keep soaring? 4 reasons why I think the answer’s ‘NO!’

Lloyds' share price has been one of the FTSE 100's strongest performers in the year to date. Could this lead…

Read more »

ISA coins
Investing Articles

How much passive income could a £20k ISA generate in a year?

The FTSE 100 could turn £20,000 into an investment returning £680 per year. But for passive income investors, that’s just…

Read more »